权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

New Faculty Recruitment to the Indiana University Gene Therapy Program

印第安纳大学基因治疗项目新教师招聘

基本信息

批准号：
7935348
负责人：
KENNETH CORNETTA
金额：
$ 28.92万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-09-30 至 2012-08-31
项目状态：
已结题

项目摘要

DESCRIPTION (provided by applicant): The Gene and Cell Therapy Program (GCTP) at Indiana University is a highly interactive group of investigators with a 15-year history of multi-departmental interaction and collaborative research. The program has a focus on the genetic manipulation of stem cells and is home to a world-class facility for the manufacture of clinical gene therapy products (funded by a NCRR construction grant). Indiana University is the NHLBI designated site for clinical lentiviral vector production through its Gene Therapy Resources Program. Indiana University is also the site of the National Gene Vector Biorepository funded by the NCRR/NIH. A NHLBI funded Program Project Grant (PI Dinauer) has facilitated the collaborations in the GCTP. Moreover, a NHLBI funded training grant in gene therapy has trained 5 pre-doctoral students and 22 post-doctoral fellows. An NIDDK training grant in hematopoiesis has trained 22 pre-doctoral students and 26 post-doctoral fellows. This P30 application will enhance this interactive group of gene and cell therapy experts while providing a proven, productive environment for the development of junior faculty. Specific Aim: The aim of this proposal is to fund recruitment of a junior faculty with expertise in gene transfer that can facilitate clinical trial and develop novel production methodology. The individual we seek to move to a tenure track position is Scott Witting, Ph.D. This P30 grant will enhance the Gene and Cell Therapy Program at Indiana University. Dr. Scott Witting will be hired as an Assistant Professor tenure track and develop an independent research program aimed at identifying the optimal, clinically relevant, gene transfer methodology for transduction of hematopoieitic and other stem cell products. This will facilitate clinical trials proposed by the GCTP members.

描述（由申请人提供）：印第安纳州大学的基因和细胞治疗项目（GCTP）是一个高度互动的研究小组，具有15年的多部门互动和合作研究历史。该计划专注于干细胞的遗传操作，并拥有世界一流的临床基因治疗产品制造设施（由NCRR建设赠款资助）。印第安纳州大学是NHLBI通过其基因治疗资源计划指定的临床慢病毒载体生产基地。印第安纳州大学也是由NCRR/NIH资助的国家基因载体生物库的所在地。 NHLBI资助的计划项目赠款（PI Dinauer）促进了GCTP的合作。此外，国家HLBI资助的基因治疗培训赠款培训了5名博士预科生和22名博士后研究员。NIDDK在造血方面的培训赠款培训了22名博士前学生和26名博士后研究员。这个P30应用程序将增强这个基因和细胞治疗专家的互动小组，同时为初级教师的发展提供一个经过验证的，富有成效的环境。具体目标：该提案的目的是资助招募一名具有基因转移专业知识的初级教师，以促进临床试验和开发新的生产方法。我们寻求移动到终身职位的个人是斯科特·威廷博士。这P30赠款将加强基因和细胞治疗计划在印第安纳州大学。Scott Witting博士将被聘为助理教授终身职位，并开发一个独立的研究计划，旨在确定造血和其他干细胞产品转导的最佳，临床相关的基因转移方法。这将促进GCTP成员提出的临床试验。